British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.
from Reuters: Health News https://ift.tt/2VndVRT
No comments:
Post a Comment